SCHEMBL5775664

SCHEMBL5775664

C(=NNc1ccc(-c2cccnc2)cc1)c1ccncc1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 10/20 0.57
NPC1 O15118 9/20 0.57
GAA P10253 7/20 0.57
MAPT P10636 9/20 0.57
SMN1; SMN2 Q16637 7/20 0.57
ALDH1A1 P00352 5/20 0.57
LMNA P02545 4/20 0.57
GFER P55789 2/20 0.57
TDP1 Q9NUW8 1/20 0.57
KMT2A Q03164 3/20 0.52
POLB P06746 3/20 0.51
THRB P10828 1/20 0.51
HDAC3 O15379 1/20 0.47
HDAC1 Q13547 1/20 0.47
HDAC2 Q92769 1/20 0.47
HDAC6 Q9UBN7 1/20 0.47
KDM4E B2RXH2 2/20 0.47
HTT P42858 1/20 0.47
CDK5 Q00535 1/20 0.47
CDK5R1 Q15078 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5773744 0.87 GAA (0.53) RAB9ANPC1GAAMAPTSMN1; SMN2
SCHEMBL5773740 0.87 GAA (0.53) RAB9ANPC1GAAMAPTSMN1; SMN2
SCHEMBL5780650 0.83 MAPT (0.49) RAB9ANPC1GAAMAPTSMN1; SMN2
SCHEMBL14438165 0.77 NOX1 (0.74) RAB9ANPC1GAAMAPTSMN1; SMN2
SCHEMBL11127219 0.77 NOX1 (0.74) RAB9ANPC1GAAMAPTSMN1; SMN2
SCHEMBL5778611 0.74 RAB9A (0.68) RAB9ANPC1GAAMAPTSMN1; SMN2
SCHEMBL14832820 0.74 RAB9A (0.97) RAB9ANPC1GAAMAPTSMN1; SMN2
SCHEMBL11127223 0.74 RAB9A (0.69) RAB9ANPC1GAAMAPTSMN1; SMN2
SCHEMBL11124641 0.74 RAB9A (0.97) RAB9ANPC1GAAMAPTSMN1; SMN2
SCHEMBL14831808 0.74 RAB9A (0.69) RAB9ANPC1GAAMAPTSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060276433-A1 Hydrazone derivative DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2006-12-07 US disclosed
EP-1612204-A1 HYDRAZONE DERIVATIVE DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2006-01-04 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060276433-A1 Hydrazone derivative APP, PRNP, HTT RAB9A 3127/4885NPC1 952/4885GAA 3175/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.